AS1411
Trial failures threaten UK biotech
February 18, 2011Research and Development AML, AS1411, AS1413, Antisoma, Juvista, Renovo, UK biotech, acute myeloid leukaemia, anti-scarring, biotech
A number of late stage failures from British biotech firms have left a looming question mark over the future of …
Latest content
Medtronic secures CE Mark for new cardiac pacing portfolio
October 30, 2026
Dermatology leader Doncker is new Onicor CEO
October 29, 2026
October 28, 2026
